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Eﬀ ect of intermittent pneumatic compression on disability, 
living circumstances, quality of life, and hospital costs after 
stroke: secondary analyses from CLOTS 3, a randomised trial
CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration*
Summary
Background The results of the CLOTS 3 trial showed that intermittent pneumatic compression (IPC) reduced the risk of 
deep vein thrombosis and improved survival in immobile patients with stroke. IPC is now being widely used in stroke 
units. Here we describe the disability, living circumstances, quality of life, and hospital costs of patients in CLOTS 3.
Methods In CLOTS 3, a parallel group trial in 94 UK hospitals, immobile patients with stroke from days 0 to 3 of 
admission were assigned with a computer-generated allocation sequence in a 1:1 ratio to IPC or no IPC through a central 
randomisation system. We followed up patients at about 6 months with postal or telephone questionnaire to assess the 
secondary endpoints: disability (Oxford Handicap Scale [OHS]), living circumstances, health-related quality of life 
(EQ5D-3L), and hospital costs (based on use of IPC and length of hospital stay). Patients and carers who completed the 
postal questionnaires were not masked to treatment allocation, but telephone follow-up in non-responders was masked. 
All analyses were by intention to treat. This trial is registered, number ISRCTN93529999.
Findings Between Dec 8, 2008, and Sept 6, 2012, we enrolled 2876 patients, with 1438 in each group. Despite the previously 
reported reduction in the risk of proximal deep vein thrombosis at 30 days (primary endpoint), there were no signiﬁ cant 
diﬀ erences in disability (OHS 0–2 vs 3–6, adjusted odds ratio [OR] 0·98, 95% CI 0·80 to 1·19, p=0·83; adjusted ordinal 
analysis common OR 0·97, 95% CI 0·86 to 1·11), living circumstances (institutional care vs not; adjusted OR 1·11, 
95% CI 0·89 to 1·37; p=0·358), or health-related quality of life (median utility value 0·26, IQR –0·07 to 0·66 with IPC, 
and 0·27, –0·06 to 0·64, with no IPC; p=0·952). The estimated cost of IPC was £64·10 per patient (SD 28·3). The direct 
costs of preventing a deep vein thrombosis and death were £1282 (95% CI 785 to 3077) and £2756 (1346 to not estimable), 
respectively, with IPC. Hospital costs increased by £451 with IPC compared with no IPC because of a longer stay in 
hospital (mean 44·5 days [SD 37·6] vs 42·8 days [37·2]; mean diﬀ erence 1·8 days, 95% CI –1·0 to 4·5). By 6 months, 
despite an increase in survival (IPC 152·5 days [SD 60·6] vs no IPC 148·1 days [64·3]; mean diﬀ erence 4·5 days, 95% CI 
–0·2 to 9·1), there was a non-signiﬁ cant increase in quality-adjusted survival associated with IPC (IPC 27·6 days 
[SD 40·6] vs no IPC 26·7 days [39·6]; mean diﬀ erence 0·9 days, 95% CI –2·1 to 3·9).
Interpretation IPC is inexpensive, prevents deep vein thrombosis, improves survival but not functional outcomes, and 
does not lead to a signiﬁ cant gain in quality-adjusted survival. When deciding whether to treat patients with IPC, 
clinicians need to take into account all these potential eﬀ ects.
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Introduction
About 110 000 patients with acute stroke are admitted to 
hospitals in the UK each year. 30-day case fatality varies, 
but is about 20%. The direct medical cost of stroke in the 
UK is estimated as £2·8 billion per year.1 Venous 
thromboembolism is common after stroke, causes 
substantial morbidity, might delay hospital discharge, 
might increase costs, and has been estimated to account 
for a quarter of all deaths after stroke.2
The results of the CLOTS 3 trial showed that 
intermittent pneumatic compression (IPC) applied to 
the legs of immobile patients with stroke reduced the 
risk of the primary outcome proximal deep vein 
thrombosis (odds ratio [OR] 0·65, 95% CI 0·51–0·84; 
p=0·001) and secondary outcomes including any deep 
vein thrombosis (0·72, 0·60–0·87; p=0·001) and 
symptomatic deep vein thrombosis (0·72, 0·52–0·99; 
p=0·045) within 30 days after randomisation.3 IPC also 
reduced the hazard of death over the ﬁ rst 6 months 
(hazard ratio 0∙85, 95% CI 0∙73–0∙99; p=0·042).3 To 
help guide the implementation of this intervention for 
patients with stroke, we aimed to describe additional 
secondary outcomes assessed at 6 months—disability, 
living circumstances, quality of life, and the hospital 
costs of patients recruited into CLOTS 3—to ascertain 
the cost-eﬀ ectiveness of preventing deep vein thrombosis 
and deaths with IPC and quality-adjusted survival in 
quality-adjusted life-days (QALDs).
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Methods
Study design and patients
The methods have been described in detail elsewhere.3–5 
Brieﬂ y, CLOTS 3 was a multicentre trial with a parallel 
group design. Patients were enrolled at 94 centres in the 
UK from days 0 (admission) to 3 in hospital and allocated 
to the IPC group or the no IPC group; all patients received 
routine care.
Patients were eligible for inclusion if they were 
admitted to hospital within 3 days of an acute stroke 
(ischaemic or haemorrhagic), could be enrolled between 
day 0 and day 3 in hospital, and were immobile (ie, 
unable to walk independently to the toilet). We excluded 
patients with subarachnoid haemorrhage and those with 
severe peripheral vascular disease, congestive heart 
failure, or skin lesions on the legs that were thought to be 
contraindications for IPC.
The study protocol was approved by the Scotland A 
Multicentre Research Ethics Committee (08/MREC00/73) 
and the Newcastle and North Tyneside 1 Research Ethics 
Committee for England (08/H0906/137). All patients 
provided written informed consent before they were 
randomly assigned to treatment.
Randomisation and masking
After obtaining consent, the clinician entered the patient’s 
baseline data into our computerised central randomisation 
service through a secure web interface. Once the computer 
program had checked these baseline data for completeness 
and consistency, it generated treatment allocation for the 
patient: routine care plus IPC or routine care without IPC. 
Patients were randomly assigned in a 1:1 ratio. Patients 
and their carers who completed follow-up questionnaires 
at 6 months were not masked to treatment allocation. 
However, the individual doing telephone follow-up of 
patients who did not respond to the postal follow-up was 
masked to treatment assignment.
Procedures
In patients allocated to the IPC group, nursing staﬀ 
applied the Kendall Express Sequential Compression 
System (Covidien, Mansﬁ eld, MA, USA) with thigh-length 
sleeves to both legs, according to the manufacturer’s 
instructions. The sleeves were to be worn 24 h per day for 
30 days or until one of the following criteria was met: a 
second screening compression duplex ultrasound had 
been done (after 30 days); the patient was independently 
mobile or discharged from the hospital in which he or she 
was randomly assigned; the patient refused to wear the 
sleeves; or the staﬀ  became concerned about the patient’s 
skin. We stipulated that both treatment groups should 
receive the same background general care, which 
included, depending on local protocols, early mobilisation, 
hydration, and antiplatelet or anticoagulant drugs.
We aimed to do a compression duplex ultrasound of the 
veins in both legs between days 7 and 10 after randomisation 
in all patients, and, whenever practical, a second scan 
between days 25 and 30. The local coordinator reviewed 
the medical record and extracted the information to 
complete our discharge form. We could not mask the local 
coordinator to group allocation because there was no sham 
version of IPC and because we were gathering data for 
adherence. At about 6 months, we sent a postal 
questionnaire to each patient’s family doctor to establish 
the patient’s vital status. We followed up surviving patients 
at 6 months after enrolment by postal questionnaire. The 
chief investigator did a telephone interview, masked to 
treatment allocation, with patients who did not respond to 
the postal questionnaire. Information about the timing 
and method of follow-up is provided in the appendix.
The numbers of IPC sleeves delivered to sites and the 
number remaining at the end of the trial were used to 
estimate the mean number of sleeves used per patient. 
We did not record the number of sleeves used by each 
participant.
Outcomes
The primary outcome in CLOTS 3 was the occurrence of 
a symptomatic or asymptomatic deep vein thrombosis in 
the popliteal or femoral veins (detected on the ﬁ rst or 
second compression duplex ultrasound as part of the 
trial protocol) or a symptomatic deep vein thrombosis in 
the popliteal or femoral veins, conﬁ rmed on imaging 
(compression duplex ultrasound or veno graphy) within 
30 days of randomisation. The secondary outcomes 
measured at 30 days were death, or any deep vein 
thrombosis or pulmonary embolism. These primary and 
secondary outcomes, and adverse eﬀ ects of IPC, 
including skin breaks and falls, have been reported 
previously.3 The secondary outcomes reported here are 
disability (Oxford Handicap Scale [OHS]),6 living 
circumstances (institutional care or home), health-
related quality of life (utilities based on EQ5D-3L7) based 
on follow-up questionnaires returned after 6 months, 
and hospital costs. We attempted to detect post-phlebitic 
leg syndrome by asking patients about leg swelling and 
ulcers at the 6-month follow-up. However, these 
questions were not validated and unlikely to be speciﬁ c 
because of the high frequency of swelling in stroke-
aﬀ ected limbs and leg ulcers of other types.
Statistical analysis
We estimated we would need 2800 patients to provide 
90% power (α=0·05) to identify a 4% absolute reduction 
in our primary outcome (ie, from 12% to 8%). For the 
purposes of all analyses, we retained participants in the 
treatment group to which they were originally assigned 
(intention-to-treat analysis). We calculated the absolute 
diﬀ erence between groups (and its 95% CI) in the 
proportion who had at least one outcome. We compared 
the proportions with primary or secondary outcomes 
using ORs and 95% CIs, adjusted with logistic regression 
for the four variables included in our minimisation 
algorithm (predicted stroke outcome, delay from stroke 
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onset to randomisation, ability of the patient to lift both 
legs oﬀ  the bed, and use of anticoagulants or alteplase). 
The OHS at ﬁ nal follow-up was analysed by 
dichotomisation (0–2 vs 3–6) with logistic regression and 
as an ordinal scale with ordinal regression. The health-
related quality of life measured with the EQ5D-3L was 
converted into a utility value based on UK population 
preferences as a range of 1·0 (perfect health) to –0·5 
(worst possible health).8 In this setting, the range of utility 
values account for health states worse than death (utility 
value 0). We used Stata (version 12) for the analysis.
Economic analysis
We did a within-trial cost-utility analysis to estimate the 
cost-eﬀ ectiveness of IPC from a health-service provider’s 
perspective on the basis of intention to treat. Patient’s 
resource use was measured with the duration of hospital 
stay for the index episode after randomisation. Resource 
use was measured as length of stay in hospital and the 
direct costs of IPC capital and equipment. Length of stay 
distributions were converted into cost estimates based on 
a per-day hospital cost. Trial-centre-speciﬁ c or region-
speciﬁ c per-day hospital costs were based on National 
Health Service (NHS) reference costs in England and 
cost information for NHS Scotland derived from the 
Scottish Health Service Costs resource.9,10 We did not 
assess the cost of nursing home or social care, or the cost 
of readmissions to hospital.
A standard multiplicative model was used to estimate 
quality-adjusted survival expressed as QALDs by the area 
under linear interpolation of the EQ5D-3L index 
trajectory for each individual with survival times, the 
EQ5D-3L utility index score at 6 months, and a modelled 
baseline EQ5D-3L utility index value (appendix).11 We did 
sensitivity analyses based on cases with complete data 
and follow-up and using multiple imputation of EQ5D-
3L. Multiple imputation with chained equations was 
used to impute missing health-related quality-of-life data 
on the EQ5D-3L questionnaire using the mi suite of 
commands in Stata (version 12).
The primary treatment eﬀ ect for the economic analysis 
was the mean incremental costs and incremental QALDs 
over 6 months after randomisation. We also estimated 
direct costs of preventing venous thrombo embolism and 
deaths within 30 days of randomisation. Generalised 
linear models were used to analyse the distribution of 
costs and QALDs separately with a general speciﬁ cation 
that allowed for diﬀ erent parametric distributions.12 We 
also assessed diﬀ erences in costs and eﬀ ects using 
econometric methods that account for the dependency 
between each outcome. Simultaneous equation 
individual level regression models were used to estimate 
the joint distribution of costs and QALDs.13 Non-
parametric bootstrapping was undertaken to assess the 
joint densities of incremental costs and incremental 
eﬀ ects and explore uncertainty in the cost-eﬀ ectiveness 
results based on 10 000 bootstrap replications using Stata 
(version 12). Probabilistic sensitivity analysis was done to 
assess the robustness of the reported results for both 
short-run QALD estimates and hospital cost distributions. 
We had planned to estimate the averted costs arising 
from the eﬀ ects of IPC on the expected incidence of deep 
vein thrombosis or pulmonary embolism. However, the 
marginal eﬀ ect of a change in the incidence of deep vein 
thrombosis or pulmonary embolism would be noted only 
for symptomatic and treated deep vein thromboses or 
pulmonary embolisms, and these were rare events. We 
did not note a substantial diﬀ erence in hospital resource 
use between the treatment groups that could be attributed 
to a change in the incidence of deep vein thrombosis or 
pulmonary embolism so we did not enter this into our 
modelling.
This trial is registered, number ISRCTN93529999.
Role of the funding source
The funders of the study had no role in study design, 
data gathering, storage, analysis, or interpretation, 
drafting of the report, or the decision to publish. All the 
authors had full access to all data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Between Dec 8, 2008, and Sept 6, 2012, we enrolled 
2876 patients in 94 hospitals in the UK and completed 
Figure 1: Trial proﬁ le
IPC=intermittent pneumatic compression. OHS=Oxford Handicap Scale. 
EQ5D-3L=health-related quality of life.
1438 allocated to IPC group 1438 allocated to no IPC group
2876 patients randomly assigned
2 withdrew consent
1436 discharge forms received 1438 discharge forms received
8 lost to follow-up
 
13 lost to follow-up
 
1428 follow-up achieved 1425 follow-up achieved
1421 OHS complete
1403 EQ5D-3L complete
1420 OHS complete
1396 EQ5D-3L complete
330 died 367 died
1098 followed up
1076 living circumstances 
known
 810 home
 266 institution
 22 missing
1058 followed up
1039 living circumstances 
known
 806 home
 233 institution
 19 missing
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follow-up in March, 2013. Figure 1 shows the trial 
proﬁ le. Patients were randomly assigned to routine care 
plus IPC (n=1438) or routine care without IPC (n=1438).
Figure 2 shows the outcomes of patients with respect to 
OHS. The prespeciﬁ ed analyses for the comparison of 
OHS in the two groups showed no signiﬁ cant diﬀ erence. 
The unadjusted and adjusted ORs based on the 
dichotomised OHS (OHS 0–2 vs 3–6) were 0·99 (95% CI 
0·83–1·19; p=0·93) and 0·98 (0·80–1·19; p=0·83), 
respectively. The ordinal analysis of the OHS yielded 
common ORs of 0·98 (95% CI 0·86–1·12) and 0·97 
(0·86–1·11), respectively. According to the results of post-
hoc and exploratory analyses, done to investigate an 
apparent increase in the proportion of patients with OHS 
5 in the IPC group, although non-signiﬁ cantly fewer 
deaths occurred in the IPC group (330 [23%] of 1421 vs 
367 [26%] of 1420; p=0·12), more patients survived with 
very poor function in the IPC group (OHS 5; 309 [22%] vs 
255 [18%]; p=0·013).
Of the patients allocated IPC, 266 (25%) of 1076 were 
living in a nursing home or were in hospital at the 
6-month follow-up compared with 233 (22%) of 1039 
allocated only routine care (unadjusted OR 1·14, 95% CI 
0·93 to 1·39, p=0·214; adjusted OR 1·11 95% CI 
0·89 to 1·37, p=0·358). The median health-related quality-
of-life utility value for survivors (based on the EQ5D-3L) 
was 0·26 (IQR –0·07 to 0·66) and 0·27 (–0·06 to 0·64) in 
the IPC and no IPC groups, respectively (p=0·952).
Table 1 shows the estimated resource use and costs. 
Patients allocated IPC had a slightly longer hospital stay 
(mean diﬀ erence 1·8 days, 95% CI –1·0 to 4·5; table 1), 
probably attributable to their improved survival. 
Individuals in the IPC group wore IPC for a mean of 
11·7 days, using a mean of 2·5 pairs of sleeves (table 1). 
On the basis of  the unit costs of sleeves (which included 
the cost of the controllers) and an estimate of the nursing 
time taken to ﬁ t and monitor them (based on our 
observations in one centre), we estimated the mean 
direct cost of IPC to be £64·10 per patient (SD 28·3) or 
£5·48 per day of treatment.
Table 2 shows the estimated direct costs of avoiding 
proximal deep vein thrombosis, any deep vein 
thrombosis, symptomatic deep vein thrombosis, 
pulmonary embolism, or death in the 30-day treatment. 
These costs do not include the increased costs (mean 
£387 [SD 306·3]) of the longer stay in hospital associated 
with the use of IPC.
Table 3 shows the diﬀ erence between treatment groups 
with respect to survival and quality-adjusted survival 
(QALDs). Despite the improved mean survival in the IPC 
group of 4·5 days (95% CI –0·2 to 9·1), there was a mean 
gain of only 0·9 days (–2·1 to 3·9) in quality-adjusted 
survival over the 6-month follow-up because of poor 
quality of life in many survivors. Missing data were few, 
but sensitivity analyses based on multiple imputations of 
the EQ5D-3L did not alter our conclusions (table 3). 
Figure 3 summarises the cost-eﬀ ectiveness results based 
on cases (n=2799) with complete data and follow-up. The 
incremental cost-eﬀ ectiveness ratio indicates that IPC 
might be used if a decision maker is willing to pay more 
than £610·88 for an additional day of quality-adjusted 
survival (ﬁ gure 3).
The data for the frequency of leg swelling and leg 
ulcers at 6-month follow-up are reported in the appendix.
IPC (n=1438) No IPC (n=1438)
Mean (SD) Median (range) Mean (SD) Median (range)
Estimated resource use
Length of hospital stay 
up to 6 months (days)
44·5 (37·6) 34 (1–184) 42·8 (37·2) 32 (1–184)
Number of sleeves per 
patient
2·5 (0·9) 2·5 (1–5) 2·5 (0·9) 3·0 (1–5)
Number of days IPC 
should have been worn
22·9 (11·2) 30·0 (0–91) 0 (0) 0 (0–0)
Number of days IPC 
was actually worn 
11·7 (10·6) 8 (0–65) 0·01 (0·3) 0 (0–12)
Estimated costs (£)
Cost of IPC 64·1 (28·3) 60·5 (0–156·9) 0·2 (3·8) 0 (0–103·5)
Cost of hospital days 12 503 (8263) 10 283 (1579–43 093) 12 116 (8163) 9694 (1595–43 129)
Cost of IPC plus 
hospital days
12 567 (8264) 10 338 (1579–43 153) 12 116 (8163) 9694 (1595–43 129)
IPC=intermittent pneumatic compression.
 Table 1: Summary of resource use and cost estimates
Cost (£; 95% CI)
Proximal deep vein thrombosis (symptomatic or asymptomatic) 1795 (1089–4551)
Any deep vein thrombosis (proximal or distal, symptomatic or asymptomatic) 1282 (785–3077)
Any symptomatic deep vein thrombosis 3546 (1923–not estimable)
Conﬁ rmed pulmonary embolism 16 025 (4295–not estimable)
Death within 30 days 2756 (1346–not estimable)
Estimates are based on the eﬀ ect of IPC on the absolute reduction of the risk of venous thromboembolism3 and the 
number needed to treat derived from the absolute risk reduction. The estimates do not include the cost (mean £387) 
of the longer stay in hospital associated with the use of IPC. Where the upper 95% CIs were compatible with IPC 
increasing the risk of an outcome, the number needed to treat to prevent that outcome becomes inﬁ nite, as does the 
cost of giving that treatment. IPC=intermittent pneumatic compression.
 Table 2: Estimates of the direct treatment cost of preventing venous thromboembolism events or death 
during treatment with IPC in immobile patients with stroke
Figure 2: Disability (OHS) in patients allocated IPC or no IPC
OHS data were missing for 17 (1%) of 1438 patients in the IPC group and 18 (1%) of 1438 in the no IPC group and 
these patients are excluded. OHS=Oxford Handicap Scale. IPC=intermittent pneumatic compression.
Number
No IPC25·86·5 11·0 22·5 13·0 18·03·2
IPC23·26·6 11·0 21·5 12·7 21·73·2
142036792 156 320 185 25545
Number 142133094 156 306 181 30945
1000 20 40 60 80
Patients (%)
0
OHS
54321 Dead
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Discussion
The previously reported results of CLOTS 3 showed that 
IPC use in hospitalised patients with stroke who are 
immobile reduces the risk of deep vein thrombosis and is 
associated with a signiﬁ cant improvement in survival over 
the ﬁ rst 6 months. However, here we show that IPC use is 
not associated with a signiﬁ cant improvement in disability, 
proportions of patients living at home, quality of life, or 
any gain in quality-adjusted survival. Nevertheless, IPC is 
an aﬀ ordable and eﬀ ective method of prophylaxis for 
venous thromboembolism, although it increases overall 
hospital costs due to increased length of stay associated 
with improved survival (panel). The direct treatment costs 
of preventing one deep vein thrombosis, or even one early 
death, are small.
The results of the post-hoc exploratory analysis of the 
OHS showed a signiﬁ cant increase in the proportion of 
patients surviving with an OHS of 5, indicating that they 
were bed or chair bound and required complete care. This 
ﬁ nding suggests that most of the deaths that might result 
from pulmonary embolism and might be prevented with 
IPC occur in patients with severe strokes who would be 
expected to have a poor functional outcome. We have 
previously shown that dependency in activities of daily 
living before stroke, greater limb weakness, and a history 
of deep vein thrombosis or pulmonary embolism are 
independently associated with an increased risk of deep 
vein thrombosis after stroke.17 Previous dependency and 
increased limb weakness are also associated with worse 
functional outcomes.18 Therefore, if IPC eﬀ ectively reduces 
the risk of deep vein thrombosis and improves survival by 
preventing fatal venous thromboembolism, many of the 
patients who survive because of IPC would be expected to 
have poor functional status. Patients with poor functional 
status have a utility as measured with EQ5D-3L that is little 
diﬀ erent from death. For this reason, there is little gain in 
quality-adjusted survival.
These secondary analyses of the CLOTS 3 trial have 
some limitations. The trial was powered to detect a 4% 
absolute reduction in the risk of proximal deep vein 
thrombosis within 30 days, but was not powered to detect 
the improvement in survival or the diﬀ erences in the 
OHS, costs, or EQ5D-3L. Also, the statistical comparison 
of the proportion of patients with OHS 5 between 
treatment groups was not prespeciﬁ ed and was done after 
the analysis of the data. Patients and their families were 
not masked to their treatment allocation, but at 6 months 
provided the information on which the OHS and quality 
of life were based. This could theoretically have introduced 
some bias, but neither patients nor their carers were likely 
to have thought that IPC would aﬀ ect outcomes other 
than venous thromboembolism. Although the EQ5D-3L 
has been used widely to estimate health-related quality of 
life and the utilities based on the preferences of UK and 
other populations are available, its validity for the 
measurement of quality of life early during hospitalisation 
with acute stroke might be questionable. Indeed, because 
of this potential caveat we modelled the baseline EQ5D-3L 
rather than attempting to measure it directly. This might 
have aﬀ ected our estimates of quality-adjusted survival, 
which depend on a change in EQ5D-3L between baseline 
and follow-up. Also, the preferences on which utility 
values are based are those of a general sample of the UK 
population rather than stroke survivors. Stroke survivors 
might value survival with poor outcome diﬀ erently. The 
lengths of stay and resulting costs of hospitalisation are 
based on UK practice where rehabilitation is often 
completed as part of the initial acute hospital admission 
episode. In countries where acute hospital stays for stroke 
are much shorter, IPC might lead to greater use of 
rehabilitation facilities or community care rather than 
acute hospital resources.
The results of previous studies have shown that poorer 
functional status 6 months after a stroke is strongly 
IPC No IPC
Number Mean (SD) Median (range) Number Mean (SD) Median (range)
Survival of 
patients with 
complete data 
(days)
1403 152·5
(60·6)
183
(0 to 183)
1396 148·1
(64·3)
183
(1 to 183)
Survival (multiple 
imputations; days)
1438 153·3
(60·0)
183
(0 to 183)
1438 149·1
(63·6)
183
(1 to 183)
QALDs of patients 
with complete 
data
1403 27·6
(40·6)
16·6
(–105·1 to 145·9)
1396 26·7
(39·6)
15·4
(–84·3 to 145·9)
QALDs (multiple 
Imputations)
1438 28·2
(40·7)
17·6
(–105·1 to 145·9)
1438 27·5
(39·8)
15·9
(–84·3 to 145·9)
The median survival was 183 days because the follow-up was curtailed at this timepoint. IPC=intermittent pneumatic 
compression. QALDs=quality-adjusted life-days.
Table 3: Overall survival and 6-month QALDs
Figure 3: Cost-eﬀ ectiveness results expressed as a cost-eﬀ ectiveness plane for IPC versus standard care
The cost-eﬀ ectiveness analysis is based on the costs of the IPC and days in hospital for 2799 patients with 
complete data and follow-up. Eﬀ ect is measured as the diﬀ erential between 6 months and modelled baseline 
EQ5D-3L, divided by two, and then multiplied by survival in days to calculate quality-adjusted life-days. 
IPC=intermittent pneumatic compression. ICER=incremental cost-eﬀ ectiveness ratio.
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associated with worse long-term survival.19 Therefore, we 
might expect the improvement in survival associated with 
IPC over the ﬁ rst 6 months after randomisation to decrease 
with longer follow-up. We plan to use routinely gathered 
mortality data in the UK to investigate this possibility.
These data raise challenging clinical and ethical 
questions for clinicians who make decisions about 
whether to give prophylaxis for venous thromboembolism 
to patients after stroke. These decisions have to be made 
in the ﬁ rst few days after stroke when the risk of venous 
thromboembolism is highest,20 despite the uncertainty of 
the outcome. IPC improves survival and some patients 
who would have died from venous thromboembolism are 
likely to make a worthwhile recovery. However, applying 
eﬀ ective prophylaxis to all immobile patients with stroke 
is likely to result in the survival of more patients who are 
severely disabled, some of whom might have a quality of 
life that is unacceptable to them or their families. 
Unfortunately, which patients might beneﬁ t or not from 
prophylaxis for venous thromboembolism with IPC is not 
easy to predict reliably within the ﬁ rst day or two after a 
severe stroke. In this respect, IPC might be likened to 
other treatments used in patients with stroke such as 
antibiotics for pneumonia and early nasogastric feeding 
in patients unable to swallow, which might increase the 
likelihood of survival but not improve functional 
outcomes.21,22 In view of the small direct costs of IPC, and 
the eﬀ ect on deep vein thrombosis and survival, the rapid 
implementation of IPC in many stroke services is perhaps 
not surprising.23 However, clinicians need to take account 
of these data in relation to functional status and quality of 
life when making decisions for individual patients.
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Panel: Research in context
Systematic review
In 2013, we reported the primary results of the CLOTS 3 trial 
that showed that intermittent pneumatic compression (IPC) 
reduced the risk of our primary outcome, symptomatic or 
asymptomatic proximal deep vein thrombosis in patients 
hospitalised after an acute stroke who were initially 
immobile.3 The results also showed a signiﬁ cant reduction in 
symptomatic deep vein thrombosis (proximal or distal) and 
an improved survival to 6 months. A systematic review14 
updated in March, 2013,3 identiﬁ ed only two other trials of 
IPC, one including 151 patients with haemorrhagic stroke 
randomly assigned to IPC and graduated compression 
stockings or to graduated compression stockings alone,15 
and the other including 26 patients with unspeciﬁ ed stroke 
randomly allocated to IPC or no IPC.16 When the results of 
CLOTS 3 were meta-analysed with the results of the other 
two trials, the estimates of treatment eﬀ ects were an odds 
ratio (OR) of 0·66 (95% CI 0·52–0·84) for proximal deep vein 
thrombosis, 0·71 (0·59–0·85) for any deep vein thrombosis, 
and 0·81 (0·65–1·01) for deaths by the end of the treatment 
period.3 Neither small trial reported any symptomatic deep 
vein thrombosis or pulmonary embolisms, a survival analysis, 
or any data for long-term disability, living circumstances, 
quality of life, or hospital costs.
Interpretation
IPC is inexpensive, prevents deep vein thrombosis, improves 
survival but not disability, and does not achieve any 
signiﬁ cant gain in quality-adjusted survival. When deciding 
whether to treat individual patients with IPC, clinicians need 
to take account of these eﬀ ects. All national guidelines 
recommending methods of prophylaxis of venous 
thromboembolism in stroke and other disorders have focused 
mainly on evidence of eﬀ ects on deep vein thrombosis, 
primarily asymptomatic deep vein thrombosis. The CLOTS 3 
results emphasise the importance of also taking account of 
outcomes such as survival, disability, and quality of life, which 
can be more important to patients and their families.
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